Zacks Investment Research upgraded shares of BAVARIAN NORDIC/S (OTCMKTS:BVNRY) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. They currently have $12.00 price target on the stock.
According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
Shares of BAVARIAN NORDIC/S stock opened at $10.46 on Monday. BAVARIAN NORDIC/S has a one year low of $6.42 and a one year high of $10.93. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.43 and a quick ratio of 7.08. The stock’s 50-day moving average is $9.33 and its 200 day moving average is $8.77. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -16.60 and a beta of 0.52.
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
Recommended Story: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.